Published in Gastroenterology on September 17, 2008
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Drug-induced autoimmune-like hepatitis. Dig Dis Sci (2011) 2.86
Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model. Clin Gastroenterol Hepatol (2015) 2.76
Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology (2015) 2.43
Bleeding complications and liver injuries during phenprocoumon treatment: a multicentre prospective observational study in internal medicine departments. Dtsch Arztebl Int (2013) 2.37
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (2010) 2.28
Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology (2010) 2.26
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Persistent Liver Biochemistry Abnormalities Are More Common in Older Patients and those With Cholestatic Drug Induced Liver Injury. Am J Gastroenterol (2015) 2.08
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Serum proteomic profiling in patients with drug-induced liver injury. Aliment Pharmacol Ther (2012) 1.55
Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology (2010) 1.51
Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol (2010) 1.50
Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome. Clin Gastroenterol Hepatol (2013) 1.46
RUCAM in Drug and Herb Induced Liver Injury: The Update. Int J Mol Sci (2015) 1.45
Diabetes mellitus and tuberculosis facts and controversies. J Diabetes Metab Disord (2013) 1.43
Management of acute liver failure. Nat Rev Gastroenterol Hepatol (2009) 1.32
Catechins in dietary supplements and hepatotoxicity. Dig Dis Sci (2013) 1.31
Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology (2014) 1.31
Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology (2013) 1.24
Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology (2014) 1.19
A collaborative approach to developing an electronic health record phenotyping algorithm for drug-induced liver injury. J Am Med Inform Assoc (2013) 1.14
Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models. Pharmacol Rev (2009) 1.12
Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev (2013) 1.12
Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr (2011) 1.12
Drug-induced liver injury: a clinical update. Curr Opin Gastroenterol (2010) 1.10
Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis (2009) 1.10
Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother (2011) 1.07
Drug-induced liver injury: present and future. Clin Mol Hepatol (2012) 1.06
Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol (2011) 1.05
Recent developments in acute liver failure. Best Pract Res Clin Gastroenterol (2012) 1.05
Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps. Front Pharmacol (2015) 1.04
Liver Injury from Herbal, Dietary, and Weight Loss Supplements: a Review. J Clin Transl Hepatol (2015) 1.03
Drug-induced acute liver failure. Clin Liver Dis (2013) 1.03
Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int (2014) 1.02
Use of transcriptomics in understanding mechanisms of drug-induced toxicity. Pharmacogenomics (2010) 1.01
An Update on Drug-induced Liver Injury. J Clin Exp Hepatol (2012) 1.01
Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol (2013) 1.01
Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase. World J Gastroenterol (2012) 0.97
Drug- and Herb-Induced Liver Injury in Clinical and Translational Hepatology: Causality Assessment Methods, Quo Vadis? J Clin Transl Hepatol (2013) 0.96
Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study. CMAJ (2012) 0.96
Spontaneously reported hepatic adverse drug events in Korea: multicenter study. J Korean Med Sci (2012) 0.95
Paracetamol in therapeutic dosages and acute liver injury: causality assessment in a prospective case series. BMC Gastroenterol (2011) 0.93
Risk of oral antifungal agent-induced liver injury in Taiwanese. Br J Clin Pharmacol (2014) 0.89
Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network. Pharmacoepidemiol Drug Saf (2012) 0.89
Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol (2014) 0.89
A panel of serum microRNAs as specific biomarkers for diagnosis of compound- and herb-induced liver injury in rats. PLoS One (2012) 0.88
Eosinophils mediate the pathogenesis of halothane-induced liver injury in mice. Hepatology (2013) 0.88
Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin Exp Immunol (2015) 0.88
Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide. Dig Dis Sci (2012) 0.88
Validity of diagnostic codes and laboratory tests of liver dysfunction to identify acute liver failure events. Pharmacoepidemiol Drug Saf (2015) 0.88
HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One (2013) 0.87
Presentation and outcomes with clinically apparent interferon beta hepatotoxicity. Dig Dis Sci (2013) 0.86
Atypical causes of cholestasis. World J Gastroenterol (2014) 0.86
N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review protocol. Syst Rev (2015) 0.86
Drug-induced liver injury caused by intravenously administered medications: the Drug-induced Liver Injury Network experience. J Clin Gastroenterol (2013) 0.85
A Text Searching Tool to Identify Patients with Idiosyncratic Drug-Induced Liver Injury. Dig Dis Sci (2015) 0.85
Time-course changes in the expression levels of miR-122, -155, and -21 as markers of liver cell damage, inflammation, and regeneration in acetaminophen-induced liver injury in rats. J Vet Sci (2016) 0.85
Hepatotoxicity by Drugs: The Most Common Implicated Agents. Int J Mol Sci (2016) 0.85
SlimQuick™ - associated hepatotoxicity in a woman with alpha-1 antitrypsin heterozygosity. World J Hepatol (2012) 0.85
Clinical Features and Outcomes of Complementary and Alternative Medicine Induced Acute Liver Failure and Injury. Am J Gastroenterol (2016) 0.85
The impact of duration of treatment on reported time-to-onset in spontaneous reporting systems for pharmacovigilance. PLoS One (2013) 0.84
Detective work in drug-induced liver injury: sometimes it is all about interviewing the right witness. Clin Gastroenterol Hepatol (2010) 0.84
Drug-Induced Liver Injury: Pattern Recognition and Future Directions. Gut Liver (2016) 0.84
Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. PLoS One (2013) 0.84
Statin therapy and hepatotoxicity: Appraisal of the safety profile of atorvastatin in hyperlipidemic patients. Adv Biomed Res (2014) 0.83
The clinical features of drug-induced liver injury observed through liver biopsy: focus on relevancy to autoimmune hepatitis. Clin Mol Hepatol (2012) 0.83
Prevalence of antibiotic use: a comparison across various European health care data sources. Pharmacoepidemiol Drug Saf (2015) 0.82
Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study. Br J Clin Pharmacol (2015) 0.82
Drug-induced liver injury due to varenicline: a case report. BMC Gastroenterol (2012) 0.82
High Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD Cohort. PLoS One (2016) 0.82
In vitro testing for diagnosis of idiosyncratic adverse drug reactions: Implications for pathophysiology. Br J Clin Pharmacol (2015) 0.81
Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia. PLoS One (2014) 0.81
The adaptive response (drug tolerance) helps to prevent drug-induced liver injury. Gastroenterol Hepatol (N Y) (2012) 0.81
An Update on Treatment of Drug-Induced Liver Injury. J Clin Transl Hepatol (2014) 0.81
Amoxicillin-Clavulanate-Induced Liver Injury. Dig Dis Sci (2016) 0.80
Herbal Medicine in Mexico: A Cause of Hepatotoxicity. A Critical Review. Int J Mol Sci (2016) 0.80
Drug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment Options. J Clin Transl Hepatol (2015) 0.80
Thymic stromal lymphopoietin and interleukin-4 mediate the pathogenesis of halothane-induced liver injury in mice. Hepatology (2014) 0.80
The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity. Int J Mol Sci (2016) 0.79
Pregnane X receptor and drug-induced liver injury. Expert Opin Drug Metab Toxicol (2014) 0.79
Metronidazole induced liver injury: a rare immune mediated drug reaction. Case Rep Gastrointest Med (2013) 0.79
Clinical perspective: statins and the liver--harmful or helpful? Dig Dis Sci (2012) 0.79
Moxifloxacin induced fatal hepatotoxicity in a 72-year-old man: a case report. Cases J (2009) 0.79
Causes, clinical features and outcomes of drug-induced liver injury in hospitalized patients in a Chinese tertiary care hospital. Springerplus (2015) 0.79
Identification and Characterization of Cefazolin-Induced Liver Injury. Clin Gastroenterol Hepatol (2014) 0.79
Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation. Liver Transpl (2012) 0.78
Causes, Features, and Outcomes of Drug-Induced Liver Injury in 69 Children from China. Gut Liver (2015) 0.78
The incidence, presentation, outcomes, risk of mortality and economic data of drug-induced liver injury from a national database in Thailand: a population-base study. BMC Gastroenterol (2016) 0.78
Integrated analysis of microRNA and mRNA expression profiles highlights the complex and dynamic behavior of toosendanin-induced liver injury in mice. Sci Rep (2016) 0.77
Nitrofurantoin immune-mediated drug-induced liver injury: a serious complication of a commonly prescribed medication. BMJ Case Rep (2014) 0.77
Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management. World J Gastroenterol (2014) 0.77
MicroRNAs in Drug-induced Liver Injury. J Clin Transl Hepatol (2014) 0.77
Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int (2015) 0.76
The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role? Biomed Res Int (2015) 0.76
Drug-induced Liver Injury. US Gastroenterol Hepatol Rev (2010) 0.76
Clinical Features of Drug-induced Liver Injury According to Etiology. J Korean Med Sci (2015) 0.76
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38
Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol (1993) 7.63
Drug-related hepatotoxicity. N Engl J Med (2006) 7.49
Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol (1990) 5.66
Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology (2002) 3.64
Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology (2005) 3.52
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Pharmacogenomics and individualized drug therapy. Annu Rev Med (2006) 2.95
Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol (1993) 2.89
Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology (2008) 2.66
Outcome and prognostic markers in severe drug-induced liver disease. Hepatology (2005) 2.36
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov (2007) 2.32
Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology (2006) 2.24
Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. J Hepatol (2007) 2.04
Factors associated with herbal therapy use by adults in the United States. Altern Ther Health Med (2007) 1.99
Drug-induced liver injury. Drug Saf (2007) 1.99
Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med (2006) 1.95
Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity. J Hepatol (2007) 1.79
Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol (2007) 1.78
Safety of green tea extracts : a systematic review by the US Pharmacopeia. Drug Saf (2008) 1.73
Herbal hepatotoxicity. Clin Liver Dis (2007) 1.68
Drug-induced liver injury network (DILIN). Hepatology (2004) 1.64
The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther (2007) 1.60
Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem Biol Interact (2004) 1.49
Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther (2006) 1.43
The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther (2007) 1.41
Diabetes increases the risk of acute hepatic failure. Gastroenterology (2002) 1.39
Idiosyncratic drug reactions: past, present, and future. Chem Res Toxicol (2007) 1.29
Drug-induced liver injury: Hy's rule revisited. Clin Pharmacol Ther (2006) 1.21
Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med (2008) 1.20
Mechanisms and outcomes of drug- and toxicant-induced liver toxicity in diabetes. Crit Rev Toxicol (2007) 1.00
What is idiosyncratic hepatotoxicity? What is it not? Hepatology (2008) 0.99
Hepatotoxicity due to extracts of Chinese green tea (Camellia sinensis): a growing concern. J Hepatol (2006) 0.97
Clinical characteristics and prognostic indicators of drug-induced fulminant hepatic failure. Hepatogastroenterology (2003) 0.97
Drug associated hepatic reactions in New Zealand: 21 years experience. N Z Med J (1996) 0.93
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab (2009) 11.46
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38
Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology (2005) 10.66
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation (2003) 4.00
Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology (2005) 3.95
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology (2009) 3.88
Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology (2006) 3.85
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res (2008) 3.36
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol (2005) 3.18
Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology (2008) 3.04
NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology (2002) 2.96
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med (2005) 2.95
Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology (2011) 2.64
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl (2005) 2.63
Endoscopic Transpapillary Gallbladder Stent Placement Is Safe and Effective in High-Risk Patients Without Cirrhosis. Dig Dis Sci (2014) 2.62
Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology (2012) 2.61
Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev (2012) 2.57
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc (2006) 2.43
Dance and reducing television viewing to prevent weight gain in African-American girls: the Stanford GEMS pilot study. Ethn Dis (2003) 2.41
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov (2007) 2.32
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (2010) 2.28
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med (2007) 2.17
Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin. FASEB J (2006) 2.16
An after-school obesity prevention program for African-American girls: the Minnesota GEMS pilot study. Ethn Dis (2003) 2.12
Hepatitis C, porphyria cutanea tarda and liver iron: an update. Liver Int (2012) 2.10
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology (2003) 2.05
Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol (2005) 2.04
Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology (2008) 2.02
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
The Fun, Food, and Fitness Project (FFFP): the Baylor GEMS pilot study. Ethn Dis (2003) 2.00
Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology (2011) 1.98
Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. Am J Gastroenterol (2007) 1.98
Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology (2005) 1.97
Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med (2006) 1.95
Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation (2004) 1.94
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis (2005) 1.93
Validity and reliability of activity measures in African-American girls for GEMS. Med Sci Sports Exerc (2003) 1.86
Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. Hepatology (2006) 1.83
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl (2005) 1.76
Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest (2006) 1.75
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology (2006) 1.73
Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review. Hepatology (2010) 1.71
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71
Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther (2002) 1.68
Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol (2011) 1.65
Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl (2007) 1.61
Hereditary hemochromatosis: time for targeted screening. Ann Intern Med (2008) 1.60
Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res (2009) 1.60
Child- and parent-targeted interventions: the Memphis GEMS pilot study. Ethn Dis (2003) 1.59
Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology (2007) 1.59
The Study of the Effects of Diet on Metabolism and Nutrition (STEDMAN) weight loss project: Rationale and design. Contemp Clin Trials (2005) 1.57
Pathological aspects of lipid peroxidation. Free Radic Res (2010) 1.56
Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl (2006) 1.55
Patient knowledge about disease self-management in cirrhosis. Am J Gastroenterol (2013) 1.55
Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology (2008) 1.53
Renal outcomes after liver transplantation in the model for end-stage liver disease era. Liver Transpl (2009) 1.49
Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl (2005) 1.47